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With the objective of reducing analysis time and maintaining good efficiency, there has
been substantial focus on high-speed chromatographic separations and ultra-performance
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is a preeminent
analytical tool for rapid biomedical analysis. In this study a simple, rapid, sensitive, and
specific ultra-performance liquid chromatography-MS/MS method was developed and
validated for quantification of the angiotensin II receptor antagonist, irbesartan (IRB), in
human plasma. After a simple protein precipitation using methanol and acetonitrile, IRB
and internal standard (IS) telmisartan were separated on Acquity UPLC BEH C18 column
(50 mm  2.1 mm, i.d. 1.7 mm, Waters, Milford, MA, USA) using a mobile phase consisted of
acetonitrile: methanol: 10 mM ammonium acetate (70: 15: 15 v/v/v) with a flow rate of
0.4 mL/min and detected MS/MS in negative ion mode. The ion transitions recorded in
multiple reaction monitoring mode werem/z 427.2/193.08 for IRB andm/z 513.2/469.3 for
IS. The assay exhibited a linear dynamic range of 2e500 ng/mL for IRB in human plasma
with good correlation coefficient of (0.995) and with a lower limit of quantitation of
2 ng/mL. The intra- and interassay precisions were satisfactory; the relative standard
deviations did not exceed 9.91%. The proposed UPLC-MS/MS method is simple, rapid, and
highly sensitive, and hence it could be reliable for pharmacokinetic and toxicokinetic study
in both animals and humans.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
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Irbesartan, 2-butyl-3-{[2-(tetrazol-5-yl)biphenyl-4-yl]-methyl}-
1,3-diazaspiro[4.4]non-1-en-4-one, is a potent and selective
angiotensin II subtype 1 receptor antagonist widely used for
the treatment of hypertension and heart failure in clinical
patients. Angiotensin II is an octapeptide regarded as themain
effector of AT1 receptor in the renineangiotensin system. It
causes vasoconstriction, tachycardia, increase of aldosterone
secretion from the adrenal cortex, and retention of sodium
and body fluid [1,2]. The oral absorption of irbesartan is rapid
and complete with an average absolute bioavailability of
60e80%. Following an oral administration of irbesartan in
therapeutic dose (75e300 mg), peak plasma concentration of
irbesartan is attained at 1.5e2 hours after dosing. Irbesartan
exhibits linear pharmacokinetics over the therapeutic dose
range [1e4]. Irbesartan also demonstrates superior antihy-
pertensive efficacy versus losartan and valsartan [5]. Angio-
tensin II receptor blockers have been the choice of drugs for
diabetic nephropathy by the World Health Organization
(WHO)/International Society of Hypertension (ISH) guidelines
[6].
A literature review revealed that there are several analyt-
ical methods reported for the quantitative estimation of IRB in
biomatrices mainly based on liquid chromatography [7e22],
capillary electrophoresis (CE) [23e26], and spectrophotometry
[27e30]. Liquid chromatography is the major method for
measurement of irbesartan in human plasma and urine. It is
combined with a UV detector [8,9], diode array detector (DAD)
[10e12], fluorescence (Flu) detector [13e17], electrospray
ionization mass spectrometric detection [18], and tandem
quadrupole mass spectrometer [19e22]. Literature survey also
revealed that there is a high variation in the limit of quanti-
tation (1e10 mg/mL) as reported by different authors [8e12].
There are many sample preparation methods used in biolog-
ical samples, such as solid-phase extraction (SPE), solid-phase
microextraction (SPME), liquideliquid extraction (LLE), and
protein precipitation [7e22]. SPE is the principal way to clean
up the biosamples, but it is complicated and time-consuming.
SPME is a very suitable sample preparation technique for a
small amount of samples, but it is not widely used in human
plasma samples. LLE has a tedious sample processing process
and is time consuming.
Ultra-performance liquid chromatography (UPLC) is a new
category of separation science that builds upon well-
established principles of liquid chromatography, using sub-
2mm porous particles. These particles operate at elevated
mobile phase linear velocities to produce significant re-
ductions in separation time and solvent consumption. Liter-
ature indicates that a UPLC system allows approximately
ninefold decreases in analysis time as compared to the con-
ventional high-performance (HP) LC system using 5-mm par-
ticle size analytical columns, and approximately threefold
decrease in analysis time in comparison with 3-mm particle
size analytical columns without compromise on overall sep-
aration [31e35]. Acquity UPLC columns contain hybrid X-Terra
sorbent, which utilizes bridged ethyl siloxane/silica hybrid
(BEH) structure, ensures the column stability under the high
pressure and wide pH range (1e12) [35]. In all documentedreferences, no UPLC-MS/MS method has been used to deter-
minate IRB presence and concentration in human plasma
until now.
The current study describes the development and valida-
tion of a UPLC method coupled with tandem mass spec-
trometry (UPLC-MS/MS) for the determination of IRB in
human plasma. The proposed method used is a relatively
simple extraction procedure using methanol and acetonitrile
to directly precipitate protein in combination with UPLC-MS/
MS detection.2. Materials and methods
Irbesartan and telmisartan were obtained from AK Scientific
Inc. (California, USA). Human plasma was obtained from
normal healthy volunteers at King Khalid University Hospital
(Riyadh, Saudi Arabia), and they were kept frozen at 20C
until analysis. HPLC-grade acetonitrile, methanol, and
ammonium acetate were obtained fromWinLab, London, UK.
All other reagents were of analytical grade unless stated
otherwise. All aqueous solutions was prepared using water
that was purified using Milli-QR Gradient A10R (Millipore,
Moscheim Cedex, France) having a pore size 0.22 mm.
2.1. Liquid chromatography
The UPLC system included quaternary solvent manager, a
binary pump, degasser, autosampler with an injection loop of
10 mL and a column heater-cooler. The separation was per-
formed on Acquity UPLC BEH C18 column (50 mm  2.1 mm,
i.d., 1.7 mm,Waters, Milford,MA, USA)maintained at 25C. The
mobile phase was composed of acetonitrile: methanol: 10 mM
ammonium acetate acid (70:15:15 v/v/v) pumped at a flow rate
of 0.4 mL/min. The injection volume was 5 mL in partial loop
mode and the temperature of the autosampler was kept at
4C.
2.2. Mass spectrometric conditions
Waters Acquity liquid chromatography system coupledwith a
Waters TQD triple quadrupole mass spectrometer was used.
Mass spectrometric detection was carried out using an elec-
trospray interface (ESI) operated in the negative ionization
mode with multiple reaction monitoring (MRM) for both IRB
and IS. Nitrogen was used as a desolvating gas at a flow rate of
500 L/h. The desolvating temperature was set at 400C and the
source temperature was set at 150C. The collision gas (argon)
flow was set at 0.1 mL/min. The capillary voltage was set at
3.2 kV. The MS analyzer parameters were as follows: LM1 and
HM1 resolution 10.0 and 8.0; ion energy 1, 1 V; LM2 and HM2
resolution 15.0 and 10.0, respectively; ion energy 2, 0.1 V, dwell
time, 0.146 seconds. The cone voltage and collision energy
were optimized in case of each analyte so as to maximize the
signal corresponding to the major transition observed in the
MS/MS spectra, following the fragmentation of the [MþH]þ
ions corresponding to the selected compounds. The Mass
Lynx software (Version 4.1, SCN 805, Waters, Milford, MA,
USA) was used to control the UPLC-MS/MS system as well as
for data acquisition and processing.
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A standard stock solution of IRB and telmisartan (IS) were
prepared by dissolving the compounds in methanol, to give a
final concentrations of 1 mg/mL. The 1 mg/mL stock solution
of IRB was serially diluted to prepare working solutions in the
required concentration range with diluent methanolewater
(60:40, v/v). The calibration standards and quality control (QC)
samples were prepared by spiking (5% of the total plasma
volume) with working solutions yielding concentration range
from 2 ng/mL to 500 ng/mL for IRB. The final concentrations
for each analyte were prepared to be 2 ng mL1, 8 ng mL1,
32 ng mL1, 64 ng mL1, 100 ng mL1, 250 ng mL1,
350 ngmL1, and 500 ngmL1. QC stock solutions for IRB were
prepared separately in methanolewater (60:40, v/v). QC sam-
ples at four different concentrations levels: 2 ng/mL lower
limit of quantitation (LLOQ), 5 ng/mL low quality control (LQC,
within 3 times of the LLOQ), 200 ng/mL middle quality control
(MQC) and 400 ng/mL high quality control (HQC) were pre-
pared in a similarmanner as the calibration standards. Spiked
plasma calibration standards and quality control samples
were kept at 80BC until assayed or used for validating the
assay procedures. The IS working solution (0.6 mg/mL) for
routine use was prepared by diluting the telmisartan stock
solution in methanol and kept in refrigerator for storage.
Plasma blank: 200 mL of plasma was spiked with 10 mL of
methanolewater (60:40, v/v).
Plasma blank with internal standard: 200 mL of plasma was
spiked 10 mL of 0.6 mg/mL IS.2.4. Sample preparation
A simple protein precipitationmethod was used to extract IRB
and the IS. Plasma samples stored at around 80C were
thawed, left for 1 hour, and vortexed for 30 seconds on room
temperature before extraction to ensure homogeneity. To
200 mL of plasma sample, 10 mL (0.6 mg/mL) of ISwas added. The
samples were vortex mixed for about 30 seconds and then
300 mL of acetonitrile was added to it and vortex mixed again
for another 30 seconds. After further vortex mixing, 300 mL of
methanol was added to the sample. The samples were again
vortex mixed gently for 1.0 minutes and the supernatant was
separated after centrifugation at 15,000g for 10 minutes and
evaporated to dryness under a gentle stream of nitrogen at
40C. The residue was reconstituted with 200 mL of meth-
anolewater (60:40, v/v) and transferred to UPLC vials. Five-mL
volumes (in partial loop with needle over the fill mode) of the
sample were subjected to the analysis by UPLC-MS/MS.
2.5. Bioanalytical method validation
A full method validation was performed according to guide-
lines set by the US Food and Drug Administration and Euro-
pean Medicines Agency (EMEA) guidelines. [36,37]. The
validation of this procedure was performed in human plasma
in order to evaluate the method in terms of selectivity, line-
arity of response, accuracy, precision, recovery, dilution
integrity, and stability of analytes during both short-termsample processing and long-term storage. Selectivity, line-
arity, and accuracy were assessed, and precision exercise
were also performed in human plasma.
2.6. Selectivity and specificity
The selectivity of the method toward endogenous plasma
matrix components, metabolites, and component medica-
tions was assessed in human blank plasma. Among the
analyzed plasma batches, the plasma batch showing no or
minimal interference at the retention time of analytes and
internal standards was selected. They were processed and
analyzed using the proposed extraction protocol spiked with
standard IRB at LLOQ level (2 ng/mL) and IS 30 ng/mL.
2.7. Carryover
Carryover effect was evaluated to ensure that the rinsing so-
lution used to clean the injection needle and port was able to
avoid any carry-forward of injected sample in subsequent
runs. The design of the experiment comprised blank plasma,
LLOQ and upper limit of quantitation (ULOQ) followed by
blank plasma to check for any possible interference due to
carryover.
2.8. Linearity and standard curve
The linearity of the method was determined by analysis of
standard plots associated with eight point standard calibra-
tion curve (2e500 ng/mL). Calibration curves from accepted
three precision and accuracy batches were used to establish
linearity. Curves were best fitted using a least-squares linear
regression model y ¼ mx þ b, weighted by 1/x2, in which y is
the peak area ratio, m is slope of the calibration curve, b is the
y-axis intercept of the calibration curve, and x is the analyte
(IRB) concentration. Back-calculations were made from these
curves to determine the concentration of IRB in each calibra-
tion standards and the resulting calculated parameters were
used to determine concentrations of analyte in quality control
samples. The determination coefficient r2 > 0.98 was desirable
for all the calibration curves. The lowest standard on the
calibration curve was to be accepted as the LLOQ, if the ana-
lyte response was at least 10 timesmore than that of drug free
(blank) extracted plasma. In addition, the analyte peak of
LLOQ sample should be identifiable, discrete, and reproducible
with accuracy within ± 20% and a precision  20%. The devi-
ation of standards other than LLOQ from the nominal con-
centration should not be > ± 15.0%.
2.9. Precision and accuracy
Intra- and interday accuracies expressed as a percentage of
deviation from the respective nominal value. The precision of
the assaywasmeasured by the percent coefficient of variation
(% CV) at four concentrations in human plasma. Intraday
precision and accuracy were assessed by analyzing six repli-
cates of the quality control samples at four levels (quality
control) during a single analytical run. The interday precision
and accuracy were assessed by analyzing 18 replicates of the
quality control samples at each level through three precision
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The deviation at each concentration level from the nominal
concentrationwas expected to bewithin ± 15.0% except LLOQ,
for which it should not be > 20.0%. Similarly, the mean accu-
racy should not deviate by ± 15.0% except for the LLOQ, where
it can be ± 20.0% of the nominal concentration.
2.10. Extraction recovery and matrix effect
To investigate extraction recovery, a set of samples (n ¼ 6 at
each low, medium, and high concentration levels in unique
lots of plasma) was prepared by spiking IRB into plasma at
5 ng/mL, 200 ng/mL, and 400 ng/mL, respectively. Each of the
samples were processed as per the procedure described pre-
viously. A second set of plasma samples was processed and
spiked postextraction with the same concentrations of IRB
and IS that actually existed in the pre-extraction spiked
samples. Extraction recovery for each analytewas determined
by calculating the ratios of the raw peak areas of the pre-
extraction spiked samples to those of the samples spiked
after extraction. Thematrix effect was evaluated by analyzing
LQC sample.
2.11. Stability and dilution integrity evaluation
Stability of IRB in plasma was assessed by analyzing six rep-
licates of QC samples at low and high concentrations under a
variety of storage and processing conditions. Six aliquots of
each low and high concentration quality control sampleswere
taken to evaluate the bench top stability (short-term stability),
freeze thaw stability, autosampler storage stability, and long-
term stability. Bench-top stabilitywas assessed after exposure
of the plasma samples to room temperature for ~6 hours,
which exceeds the residence time of the sample processing
procedures. The freezeethaw stability was evaluated after
undergoing three freeze (at around 80C)ethaw (room tem-
perature) cycles. The autosampler storage stability was
determined by storing the reconstituted QC samples for ~48
hours under autosampler condition (maintained at 8C) before
being analyzed. Long-term stability was assessed after storage
of the test samples at around 80C for 60 days. The working
solutions and stock solutions of IRB and the IS were also
evaluated for stability at room temperature for 24 hours and at
refrigerator temperature (< 10C) for 30 days. All stabilityFig. 1 e Chemical structure of (A) irbexercises were performed against freshly spiked calibration
standards. The samples were considered stable in plasma at
each concentration if the deviation from the mean calculated
concentration of stability quality control samples was within
± 15%.
The dilution integrity experiment was intended to validate
the dilution test to be carried out on higher analyte concen-
trations (above ULOQ), which may be encountered during real
subject samples analysis. It was performed at 1.6 times the
ULOQ concentration. Six replicates samples of half and
quarter concentration were prepared and their concentra-
tionswere calculated by applying the dilution factor of 2 and 4,
respectively, against the freshly prepared calibration curve.
The integrity of the sampleswere considered to bemaintained
if % nominal is within ± 15% of nominal values and % CVs 
15 % at both diluted levels.3. Results and discussion
3.1. Optimization of chromatographic condition
Initial feasibility experiments of various mixture(s) of organic
solvents such as acetonitrile and methanol along with Milli-
pore water; also, these organic solvents along with different
concentration of ammonium acetate (2e15 mM) with altered
flow rates (in the range of 0.20e0.50 mL/min) was performed
to optimize an effective chromatographic conditions of IRB
and IS (chemical structures given in Fig. 1). The best condi-
tions were achieved with mobile phase comprising acetoni-
trile: methanol: 10 mM ammonium acetate (70:15:15 % v/v/v)
pumped at a flow rate of 0.4mL/min, on Acquity UPLC BEHC18
column (50 mm  2.1 mm, i.d. 1.7 mm. The selected conditions
were found to be suitable for the determination of electro-
spray response for IRB and IS.
UPLC-MS/MS operation parameters were carefully opti-
mized for the determination of IRB. Analytes were detected by
tandemmass spectrometry using MRM of precursoreproduct
ion transitions with 0.146 seconds dwell time, at m/z
427.2/193.08 for IRB and m/z 513.2/469.3 for IS. A standard
solution (100 ng/mL) of IRB and the IS were directly infused
along with the mobile phase into the mass spectrometer with
ESI as the ionization source. The mass spectrometer was
tuned initially in both positive and negative ionization modesesartan and (B) telmisartan (IS).
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ion was much higher. Parameters, such as capillary and cone
voltage, desolvation temperature, ESI source temperature,
and flow rate of desolvation gas and cone gas, were optimized
to obtain the optimum intensity of protonated molecules of
IRB and IS for quantification. Among the parameters, capillary
and cone voltage, especially cone voltage, were important
parameters. Analytes produced the strongest ion signals
when cone voltage was set up at 42 V. The cone voltage was
optimized using cone ramp (2e100 V) and it was noticed that
when the cone voltage was < 42 V the ion signals decreased
rapidly, however, if the cone voltage was higher it had no
effect on the ion signal. The collision energy was investigated
from 2 eV to 80 eV to optimize the response of product ion,
and the best values were found to be 28 eV for the chosen
product ions m/z 193.08. For IS, m/z 469.3 spectra was pro-
duced at cone voltage of 48 eV optimum collision energy of
34 eV.
3.2. Optimization of sample processing
Protein precipitation was used for sample preparation in
this study. Protein precipitation can be helpful in producing
a clean sample and avoiding endogenous substances inFig. 2 e (A) Representative chromatograms of blank, (B) telmisar
quality control. (E) Representative chromatograms of high-quali
quality control IS in human plasma.plasma with the analytes and IS onto the column and MS
system. Clean samples are essential for minimizing ion
suppression and matrix effect in UPLC-MS/MS analysis.
Two organic solvents, acetonitrile and methanol, were used
for precipitation of these proteins. Finally, a combination of
methanol and acetonitrile was found to be optimal, which
can produce a clean chromatogram for a blank plasma
sample and yield the highest recovery for the analytes from
the plasma.
3.3. Selectivity
Selectivity of the method was assessed by comparing the
chromatogram of blank plasma with the corresponding
spiked LLOQ sample. Six different batches of blank human
plasma were tested to identify the peaks due to the possible
biogenic plasma components. Thus, the method looks to be
selective enough for determination of IRB and IS in plasma.
Representative chromatograms obtained from blank plasma
showing no interference at the retention time of analyte and
IS are shown in Figs. 2A and 2B, respectively. A representative
chromatogram of LLOQ and LQC are shown in Figs. 2C and 2D,
respectively, whereas representative chromatogram HQC and
IS are shown in Figs. 2E and 2F, respectively.tan (IS) in blank, (C) lower limit of quantitation, and (D) low
ty control of irbesartan (IRB) in human plasma and (F) high-
Table 2 e Recovery data of irbesartan (three quality
control samples) and telmisartan in human plasma.
Compound Nominal conc. (ng/mL) Recovery (% ± SD)
IRB (analyte) 5 84.13 ± 4.87
200 80.37 ± 3.23
400 84.33 ± 4.36
Mean ± SD 82.94 ± 2.22
Telmisartan (IS) 30 84.62 ± 3.86
Conc. ¼ concentration; IRB ¼ irbesartan.
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The linearity of the method was determined by a weighted
least-squares regression analysis of standard plot associated
with an eight-point standard curve. The calibration curves
were generated by plotting area ratio (IRB/IS) as a function of
IRB concentration. It was found to be linear from 2 ng/mL to
500 ng/mL for IRB in human plasma. The determination co-
efficients (r2) were consistently > 0.995 during the course of
validation. The lower limit of quantification for this assay was
1 ng/mL in plasma. Representative LLOQ is sensitive enough
to investigate the pharmacokinetic behavior of IRB in human
plasma.3.5. Precision and accuracy
Table 1 summarizes the inter and intraday precision and ac-
curacy values for QC samples. The coefficient of variation
values of both intra and interday results of plasma were
1.06e9.91% and 0.69e2.31%, respectively. These results indi-
cate that themethod has good precision and accuracy and are
within the acceptance limit of < 15 % and ± < 15 % for preci-
sion and accuracy, respectively.3.6. Recovery
At three QC concentration levels (5 ng/mL, 200 ng/mL, and
400ng/mL), thepercentextractionrecoveries (mean±standard
deviation) of IRB obtained are given in Table 2. The mean
extraction recovery for IRB was 82.94 ± 2.22%. The mean
recovery for the IS telmisartan at the concentration used was
84.62 ± 3.86%. This result indicates that the extraction
efficiency for IRB using protein precipitation method was
satisfactory, consistent, and concentration independent.Table 1 e Intra- and interday precision and accuracy of











Intraday variation (6 replicates at each concentration)
2 1 2.04 ± 0.20 9.91 102.15
2 1.95 ± 0.14 7.60 98.25
3 1.96 ± 0.05 7.74 98.08
5 1 4.95 ± 0.20 4.08 99.06
2 4.86 ± 0.41 8.53 97.23
3 4.97 ± 0.22 4.54 99.50
200 1 197.75 ± 16.50 8.34 98.87
2 202.35 ± 15.35 7.58 101.17
3 199.96 ± 18.64 9.32 99.98
400 1 407.38 ± 9.81 2.41 101.84
2 413.06 ± 4.72 1.06 103.26
3 409.80 ± 13.88 3.38 102.45
Interday variation (18 replicates at each concentration)
2 1.98 ± 0.04 2.31 99.49
5 4.92 ± 0.06 1.21 98.59
200 200.02 ± 2.30 1.15 100.01
400 410.08 ± 2.85 0.69 102.53
Conc. ¼ concentration; CV ¼ coefficient of variation.3.7. Matrix effect
In this study, the matrix effect was evaluated by analyzing
MQC sample. The matrix effect was calculated via the
formula:
Matrix effect (%) ¼ X2/X1  100 (%) (1)
where X1 is the response of neat concentrations and X2 is
the response of post-spiked concentrations.
From the calculations, it was observed that IRB showed an
average (n¼ 6) matrix factor of 100.38% at MQC level with a CV
of 1.15%.
3.8. Stability and dilution integrity
The stabilities of IRB were investigated at two concentrations
of QC samples (low and high concentrations) to cover ex-
pected conditions during analysis, storage, and processing of
all samples, which include the stability data from various
stability exercises such as in-injector, bench-top, freeze/thaw,
and long-term stability tests. The stability results summarized
in Table 3 showed that IRB spiked into human plasma was
stable for at least 6 hours at room temperature, for at least 48
hours in final extract at 8C under autosampler storage con-
dition, for 30 days at around 80C, and during three freeze-
ethaw cycles when stored at around 80C and thawed to
room temperature. The stock solutions and working standard
of IRB and IS were stable for 30 days at refrigerator tempera-
ture (< 10C) and at least for 24 hours at room temperature.
In dilution integrity study, the % accuracy of two and four
times diluted sample was 100.80% and 100.40% of the nominal
concentration for IRB. These results conclude that the dilution
of the concentrated plasma sample up to four timesmaintains
legibility and integrity of IRB concentration.
3.9. Advantages of the proposed method over the
reported methods
This study represents the first report describing the determi-
nation of IRB in human plasma by UPLC-MS/MS method. The
proposedmethod is superior to the previously reported LC-MS
methods in terms of the simplicity as the method described
herein is based on the simple one-step protein precipitation
for sample preparation. The run time was only 2 minutes,
which is suitable for high-throughput analysis and reduction
in the use of organic solvents as flow rate of 0.4 mL/min was
used for just 2 minutes for each sample run.
Table 3 e Stability and dilution integrity data of irbesartan in human plasma.
Stability Nominal conc. (ng/mL) Measured conc. (ng/mL ± SD) Precision (CV, %) Accuracy (recovery, %)
Bench top (6 h) 5 5.02 ± 0.39 7.80 100.50
400 390.57 ± 8.67 2.22 97.64
Freeze thaw (3 cycle) 5 5.14 ± 0.52 10.21 102.21
400 401.86 ± 7.92 1.95 101.29
Auto sampler (48 h) 5 4.96 ± 0.23 4.72 99.23
400 396.02 ± 10.71 2.70 99.00
30 days at 80C 5 4.92 ± 0.39 7.92 97.41
400 405.36 ± 6.20 1.53 101.34
Dilution integrity 160 161.29 ± 9.65 5.98 100.80
320 321.28 ± 9.77 3.04 100.40
CV ¼ coefficient of variation.
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A novel simple, economical high-throughput, and highly
sensitive UPLC-MS/MS method was successfully developed
and validated for the determination of IRB in human plasma.
The method involved simple one-step protein precipitation
method for plasma sample preparation for analysis and short
runtime (2.0 minutes). The proposed method could be prac-
tical and reliable for pharmacokinetic and toxicokinetic study
for IRB in humans.Conflicts of interest
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